Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 16:05 ET | Source: Fluidigm Corporation

Fluidigm Announces Second Quarter 2020 Financial Results

Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
August 04, 2020 08:30 ET | Source: Fluidigm Corporation

Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
July 31, 2020 11:10 ET | Source: Fluidigm Corporation

Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
July 20, 2020 08:30 ET | Source: Fluidigm Corporation

GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform

Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs...
July 06, 2020 16:02 ET | Source: Fluidigm Corporation

Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
June 29, 2020 08:30 ET | Source: Fluidigm Corporation

Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay

Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments ...
June 24, 2020 08:30 ET | Source: Fluidigm Corporation

Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform

iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and...
June 17, 2020 08:30 ET | Source: Fluidigm Corporation

New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System

Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry Providing Researchers with Expanded Capabilities in Interrogating the Tissue Microenvironment SOUTH...
June 12, 2020 20:00 ET | Source: Fluidigm Corporation

Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19

Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day Easy-to-Administer Saliva Test Would Eliminate Need for Invasive Nasopharyngeal Swab High-Throughput Assay...
May 19, 2020 08:30 ET | Source: Fluidigm Corporation

University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...